SPORE for Translational Approaches to Brain Cancer
SPORE for Translational Approaches to Brain Cancer
批准号:
10626391
负责人:
MACIEJ S LESNIAK
金额:
$204.5万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-08-17 至 2028-07-31
关键词:
AddressAnabolismAutologousB-LymphocytesBiogenesisBiological MarkersBrainBrain NeoplasmsCD8-Positive T-LymphocytesCanis familiarisCathetersCellsCellular StressCharacteristicsClinical DataClinical TrialsComplexDNA DamageDataDiagnosisDiseaseEnzymesFacultyFutureGlioblastomaGliomaGoalsHumanIMPDH2 geneImmune responseImmunityImmunotherapeutic agentIncidenceIndividualInflammatoryInfusion proceduresInjectionsInterferon Type IIInterferonsIntracranial NeoplasmsMGMT geneMalignant - descriptorMalignant GliomaMalignant NeoplasmsMalignant neoplasm of brainMaximum Tolerated DoseModelingMolecularMonitorMusN-AcetylcysteinamideNatureNeoplasmsNewly DiagnosedOperative Surgical ProceduresOrganOutpatientsPathway interactionsPatient SelectionPatient-Focused OutcomesPatientsPersonsPhasePhysiologic pulsePositron-Emission TomographyPrediction of Response to TherapyPredispositionPrimary Brain NeoplasmsPrognosisPublic HealthPurinesRadiationRecordsRecurrenceResearchResearch PersonnelSTING agonistsScienceSystemT-LymphocyteTNFRSF5 geneTalentsTestingTherapeuticTimeTranslationsTreatment EfficacyTreatment outcomeTumor AntigensVaccinesanti-PD-L1armbiomarker identificationchemoradiationcohortconditionally replicative adenoviruscytotoxicityefficacy evaluationfirst-in-humanhuman studyimprovedimproved outcomeinterdisciplinary approachmanufacturemembermouse modelmycophenolate mofetilnerve stem cellnovelnovel therapeuticsoncolytic adenovirusoncolytic virotherapypre-clinicalpre-clinical researchpreventprogramsresponseresponse biomarkersafety and feasibilitysensorstandard of carestatisticssuccesssurvivorshiptemozolomidetherapeutic vaccinetranslational approachtreatment optimizationtumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
OVERALL: SUMMARY
The overall objective of the Northwestern Brain Tumor SPORE is to improve outcomes for brain tumor
patients. Of the various primary intracerebral neoplasms, glioblastoma (GBM) is the most common. GBM
patients that receive standard-of-care treatment have a median survival of 20 months, and 5-year survival is
extremely rare. Progress in developing better treatments for this lethal tumor has been disappointing. A major
contributor to this lack of therapeutic improvement is the delicate nature of the organ in which this cancer
occurs. There are significant limitations to how aggressively GBM patients can be treated surgically, and the
efficacy of systemically administered therapies are often compromised due to limited access to the brain. To
address the public health problem that is associated with glioblastoma, we have assembled a talented team of
investigators with extensive backgrounds in brain tumor research and therapy. All members of this team have
professional records indicating success in directing their own programs of research. Together, these faculty
initiated group interactions in order to bring a team science approach to bear upon the study and treatment of
GBM, and for which a multidisciplinary approach is needed for achieving meaningful progress.
期刊论文(58)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.celrep.2023.112127
发表时间:
2023-02-28
期刊:
Cell reports
影响因子:
8.8
作者:
[]
通讯作者:
Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting.
美国临床肿瘤学会 2022 年年会上的神经肿瘤学。
DOI:
10.1093/nop/npac071
发表时间:
2022
期刊:
Neuro-oncology practice
影响因子:
2.7
作者:
[Lukas,RimasV, Chmura,StevenJ, Parney,IanF, Mammoser,Aaron, Smith,SonaliM, Li,Jing]
通讯作者:
Li,Jing
Prohibitin Expression in Antigen-Presenting Cells: Implications for Inciting Trigger in CNS IgG4-Related Disease.
抗原呈递细胞中的抑制素表达:对中枢神经系统 IgG4 相关疾病的刺激触发的影响。
DOI:
10.29011/2574-7754.101607
发表时间:
2024
期刊:
Annals of case reports
影响因子:
--
作者:
[Najem,Hinda, Arrieta,VictorA, Duffy,Joseph, Tripathi,Shashwat, Zannikou,Markella, Dhiantravan,Silpol, Miska,Jason, McCortney,Kathleen, Steffens,Alicia, Walshon,Jordain, LeeChang,Catalina, Dahdaleh,NaderS, Sonabend,AdamM, Smith,Zachary, H]
通讯作者:
H
2018 Richards Medal Address: Rational Vaccinology: In Pursuit of the Perfect Vaccine.
2018 年理查兹奖章演讲:理性疫苗学:追求完美疫苗。
DOI:
--
发表时间:
2019
期刊:
Nucleus (Cambridge, Mass.)
影响因子:
--
作者:
[Mirkin,ChadA]
通讯作者:
Mirkin,ChadA
DOI:
10.4103/sni.sni_156_18
发表时间:
2018
期刊:
Surgical neurology international
影响因子:
--
作者:
[Winkel M, Lawton CD, Sanusi OR, Horbinski CM, Dahdaleh NS, Smith ZA]
通讯作者:
Smith ZA
共 30 条
Arginine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma
-
批准号:10554277
-
项目类别:
-
资助金额:$37.6万
-
财政年份:2020
-
负责人:MACIEJ S LESNIAK
-
依托单位:
phase 1 adaptive dose-escalation study of mycophenolate mofetil (MMF) in combination with temozolomide (TMZ) for patients with newly diagnosed glioblastoma
-
批准号:10468352
-
项目类别:
-
资助金额:$34.21万
-
财政年份:2020
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Arginine Metabolism Regulates Myeloid Immune Suppression in Glioblastoma
-
批准号:10331872
-
项目类别:
-
资助金额:$37.6万
-
财政年份:2020
-
负责人:MACIEJ S LESNIAK
-
依托单位:
SPORE for Translational Approaches to Brain Cancer
-
批准号:10224120
-
项目类别:
-
资助金额:$213.9万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
SPORE for Translational Approaches to Brain Cancer
-
批准号:10478866
-
项目类别:
-
资助金额:$213.9万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Neural Stem Cell Based Virotherapy for Malignant Glioma
-
批准号:10626393
-
项目类别:
-
资助金额:$27.84万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Project 1: Neural Stem Cell Based Oncolytic Virotherapy of Malignant Glioma
-
批准号:10478872
-
项目类别:
-
资助金额:$27.85万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
SPORE for Translational Approaches to Brain Cancer
-
批准号:9981687
-
项目类别:
-
资助金额:$218.5万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Administrative Core
-
批准号:10224121
-
项目类别:
-
资助金额:$12.91万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Developmental Research Program
-
批准号:10224128
-
项目类别:
-
资助金额:$17.57万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Administrative Core
-
批准号:10626392
-
项目类别:
-
资助金额:$16.37万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Administrative Core
-
批准号:10478868
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
SPORE for Translational Approaches to Brain Cancer
-
批准号:9766222
-
项目类别:
-
资助金额:$213.9万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Career Enhancement Program
-
批准号:10626400
-
项目类别:
-
资助金额:$9.85万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Project 1: Neural Stem Cell Based Oncolytic Virotherapy of Malignant Glioma
-
批准号:10224124
-
项目类别:
-
资助金额:$28.8万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Developmental Research Program
-
批准号:10478880
-
项目类别:
-
资助金额:$14.21万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Developmental Research Program
-
批准号:10626399
-
项目类别:
-
资助金额:$17.25万
-
财政年份:2018
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Therapeutic Targeting of Malignant Glioma Stem Cells
-
批准号:9126489
-
项目类别:
-
资助金额:$92.31万
-
财政年份:2015
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Therapeutic Targeting of Malignant Glioma Stem Cells
-
批准号:9981669
-
项目类别:
-
资助金额:$91.7万
-
财政年份:2015
-
负责人:MACIEJ S LESNIAK
-
依托单位:
Metabolic Control of Immune Suppression in Gliomas
-
批准号:9113102
-
项目类别:
-
资助金额:$48.49万
-
财政年份:2015
-
负责人:MACIEJ S LESNIAK
-
依托单位:
海外基金